BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 34702045)

  • 21. Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy.
    Jhaveri K; Teplinsky E; Silvera D; Valeta-Magara A; Arju R; Giashuddin S; Sarfraz Y; Alexander M; Darvishian F; Levine PH; Hashmi S; Zolfaghari L; Hoffman HJ; Singh B; Goldberg JD; Hochman T; Formenti S; Esteva FJ; Moran MS; Schneider RJ
    Clin Breast Cancer; 2016 Apr; 16(2):113-22.e1. PubMed ID: 26774497
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Higher miR-21 expression in invasive breast carcinomas is associated with positive estrogen and progesterone receptor status in patients from Serbia.
    Petrović N; Mandušić V; Dimitrijević B; Roganović J; Lukić S; Todorović L; Stanojević B
    Med Oncol; 2014 Jun; 31(6):977. PubMed ID: 24781337
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Microsatellite alterations on human chromosome 11 in in situ and invasive breast cancer: a microdissection microsatellite analysis and correlation with p53, ER (estrogen receptor), and PR (progesterone receptor) protein immunoreactivity.
    Shen KL; Yang LS; Hsieh HF; Chen CJ; Yu JC; Tsai NM; Harn HJ
    J Surg Oncol; 2000 Jun; 74(2):100-7. PubMed ID: 10914818
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epigenomic and Transcriptomic Characterization of Secondary Breast Cancers.
    Graff-Baker AN; Orozco JIJ; Marzese DM; Salomon MP; Hoon DSB; Goldfarb M
    Ann Surg Oncol; 2018 Oct; 25(10):3082-3087. PubMed ID: 29956094
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HPK1 positive expression associated with longer overall survival in patients with estrogen receptor-positive invasive ductal carcinoma‑not otherwise specified.
    Wang J; Song L; Yang S; Zhang W; Lu P; Li S; Li H; Wang L
    Mol Med Rep; 2017 Oct; 16(4):4634-4642. PubMed ID: 28765906
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic variables in invasive breast cancer: contribution of comedo versus noncomedo in situ component.
    Brower ST; Ahmed S; Tartter PI; Bleiweiss I; Amberson JB
    Ann Surg Oncol; 1995 Sep; 2(5):440-4. PubMed ID: 7496840
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tubular carcinoma and grade 1 (well-differentiated) invasive ductal carcinoma: comparison of flat epithelial atypia and other intra-epithelial lesions.
    Kunju LP; Ding Y; Kleer CG
    Pathol Int; 2008 Oct; 58(10):620-5. PubMed ID: 18801081
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Survival analysis in patients with invasive lobular cancer and invasive ductal cancer according to hormone receptor expression status in the Korean population.
    Kwon D; Ko BK; Jung SP; Kim HK; Kim EK; Jung YS; Youn HJ; Lee SB
    PLoS One; 2022; 17(1):e0262709. PubMed ID: 35051228
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-α expression in invasive ductal breast cancer patients and correlations with prognosis.
    Yan J; Liu XL; Han LZ; Xiao G; Li NL; Deng YN; Yin LC; Ling LJ; Yu XY; Tan CL; Huang XP; Liu LX
    Asian Pac J Cancer Prev; 2015; 16(2):823-9. PubMed ID: 25684532
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical significance of DJ-1 as a secretory molecule: retrospective study of DJ-1 expression at mRNA and protein levels in ductal carcinoma of the breast.
    Tsuchiya B; Iwaya K; Kohno N; Kawate T; Akahoshi T; Matsubara O; Mukai K
    Histopathology; 2012 Jul; 61(1):69-77. PubMed ID: 22385318
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast.
    Marmor S; Hui JYC; Huang JL; Kizy S; Beckwith H; Blaes AH; Rueth NM; Tuttle TM
    Cancer; 2017 Aug; 123(16):3015-3021. PubMed ID: 28382636
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The prognosis of invasive ductal carcinoma, lobular carcinoma and mixed ductal and lobular carcinoma according to molecular subtypes of the breast.
    Zhao H
    Breast Cancer; 2021 Jan; 28(1):187-195. PubMed ID: 32812198
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation of the ultrasound imaging of breast cancer and the expression of molecular biological indexes.
    Xu J; Li F; Chang F
    Pak J Pharm Sci; 2017 Jul; 30(4(Suppl.)):1425-1430. PubMed ID: 29043992
    [TBL] [Abstract][Full Text] [Related]  

  • 34. H3K27 acetylation activated long noncoding RNA RP11-162G10.5 promotes breast cancer progression via the YBX1/GLO1 axis.
    Xie N; Zhang R; Bi Z; Ren W; You K; Hu H; Xu Y; Yao H
    Cell Oncol (Dordr); 2023 Apr; 46(2):375-390. PubMed ID: 36576700
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 14-3-3ζ promoted invasion and lymph node metastasis of breast invasive ductal carcinoma with HER2 overexpression.
    Wan D; Zhang Y; Yu Q; Li F; Zhuo J
    Pathol Res Pract; 2021 Nov; 227():153619. PubMed ID: 34560418
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion.
    Elsarraj HS; Hong Y; Valdez KE; Michaels W; Hook M; Smith WP; Chien J; Herschkowitz JI; Troester MA; Beck M; Inciardi M; Gatewood J; May L; Cusick T; McGinness M; Ricci L; Fan F; Tawfik O; Marks JR; Knapp JR; Yeh HW; Thomas P; Carrasco DR; Fields TA; Godwin AK; Behbod F
    Breast Cancer Res; 2015 Sep; 17():128. PubMed ID: 26384318
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of Paget disease on axillary lymph node metastases and survival in invasive ductal carcinoma.
    Wong SM; Freedman RA; Sagara Y; Stamell EF; Desantis SD; Barry WT; Golshan M
    Cancer; 2015 Dec; 121(24):4333-40. PubMed ID: 26376021
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of calretinin in high-grade hormone receptor-negative invasive breast carcinomas: correlation with histological and molecular subtypes.
    Micello D; Bossi A; Marando A; Dainese E; Sessa F; Capella C
    Virchows Arch; 2017 Jul; 471(1):13-21. PubMed ID: 28550498
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
    Steinman S; Wang J; Bourne P; Yang Q; Tang P
    Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinicopathological significance of CADM4 expression in invasive ductal carcinoma of the breast.
    Jang SM; Sim J; Han H; Ahn HI; Kim H; Yi K; Jun YJ; Rehman A; Chung MS; Jang K; Paik SS
    J Clin Pathol; 2013 Aug; 66(8):681-6. PubMed ID: 23559354
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.